Skip to main content

Table 5 Changes in blood cell counts and uric acid

From: Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

Parameters Dapagliflozin group Metformin group P value
White blood cell count (/μL)
 Baseline 6378.6 ± 1553.5 (36) 6405.0 ± 1507.6 (36) 0.94
 Week 16 6532.5 ± 1646.0 (35) 6372.6 ± 1700.5 (34) 0.69
 Change 103.8 ± 1166.7 (34) −106.2 ± 1183.0 (34) 0.46
 P value within group 0.61 0.60 0.95
Red blood cell count (×104/μL)
 Baseline 468.9 ± 40.2 (36) 468.3 ± 41.8 (36) <0.001
 Week 16 493.6 ± 41.6 (35) 456.6 ± 42.9 (34) <0.001
 Change 26.3 ± 16.3 (34) −12.0 ± 17.5 (34)  
 P value within group <0.001 <0.001  
Hemoglobin (g/dL)
 Baseline 14.3 ± 1.3 (36) 14.4 ± 1.3 (36) 0.70
 Week 16 14.9 ± 1.4 (35) 14.2 ± 1.7 (34) 0.05
 Change 0.7 ± 0.5 (34) −0.2 ± 0.9 (34) <0.001
 P value within group <0.001 0.21  
Hematocrit (%)
 Baseline 42.6 ± 3.6 (36) 42.7 ± 3.3 (36) 0.94
 Week 16 44.7 ± 3.5 (35) 41.8 ± 3.6 (34) 0.001
 Change 2.2 ± 1.4 (34) −0.9 ± 1.8 (34) <0.001
 P value within group <0.001 0.006  
Platelet count (×104/μL)
 Baseline 24.0 ± 6.4 (36) 24.0 ± 5.0 (36) 0.99
 Week 16 23.9 ± 6.3 (35) 24.5 ± 4.7 (34) 0.64
 Change −0.3 ± 1.5 (34) 0.5 ± 2.2 (34) 0.09
 P value within group 0.20 0.25  
Uric acid (mg/dL)
 Baseline 5.6 ± 1.1 (37) 5.8 ± 1.2 (37) 0.41
 Week 16 4.9 ± 1.1 (36) 5.9 ± 1.1 (36) <0.001
 Change −0.6 ± 0.7 (36) 0.1 ± 0.6 (36) <0.001
 P value within group <0.001 0.43  
  1. Data are mean ± standard deviation (n). P values show results of comparisons between groups by t test. P values within groups are results of paired t test